Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;114:2679-2684
Published online before print December 4, 2006, doi: 10.1161/CIRCULATIONAHA.106.644203
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
114/24/2679    most recent
CIRCULATIONAHA.106.644203v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyamoto, K.
Right arrow Articles by Takeshita, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyamoto, K.
Right arrow Articles by Takeshita, S.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Bone Marrow Transplantation
Related Collections
Right arrow Peripheral vascular disease
Right arrow Angiogenesis

(Circulation. 2006;114:2679-2684.)
© 2006 American Heart Association, Inc.


Vascular Medicine

Unblinded Pilot Study of Autologous Transplantation of Bone Marrow Mononuclear Cells in Patients With Thromboangiitis Obliterans

Koji Miyamoto, MD; Kazuhiro Nishigami, MD; Noritoshi Nagaya, MD; Koichi Akutsu, MD; Masaaki Chiku, MD; Masataka Kamei, MD; Toshihiro Soma, MD; Shigeki Miyata, MD; Masahiro Higashi, MD; Ryoichi Tanaka, MD; Takeshi Nakatani, MD; Hiroshi Nonogi, MD; Satoshi Takeshita, MD

From the Departments of Medicine (K.M., K.N., K.A., M.C., H.N., S.T.), Regenerative Medicine and Tissue Engineering (N.N.), Anesthesiology (M.K.), Transfusion Medicine (S.M.), Radiology (M.H., R.T.), and Organ Transplantation (T.N.), National Cardiovascular Center, Osaka; and the Department of Clinical Laboratory (T.S.), Osaka Minami Medical Center, Osaka, Japan.

Correspondence to Dr Satoshi Takeshita, MD, FACC, Department of Medicine (Cardiology), National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. E-mail stake{at}muse.ocn.ne.jp

Received June 9, 2006; revision received September 19, 2006; accepted September 21, 2006.

Background— The short-term clinical benefits of bone marrow mononuclear cell transplantation have been shown in patients with critical limb ischemia. The purpose of this study was to assess the long-term safety and efficacy of bone marrow mononuclear cell transplantation in patients with thromboangiitis obliterans.

Methods and Results— Eleven limbs (3 with rest pain and 8 with an ischemic ulcer) of 8 patients were treated by bone marrow mononuclear cell transplantation. The patients were followed up for clinical events for a mean of 684±549 days (range 103 to 1466 days). At 4 weeks, improvement in pain was observed in all 11 limbs, with complete relief in 4 (36%). Pain scale (visual analog scale) score decreased from 5.1±0.7 to 1.5±1.3. An improvement in skin ulcers was observed in all 8 limbs with an ischemic ulcer, with complete healing in 7 (88%). During the follow-up, however, clinical events occurred in 4 of the 8 patients. The first patient suffered sudden death at 20 months after transplantation at 30 years of age. The second patient with an incomplete healing of a skin ulcer showed worsening of the lesion at 4 months. The third patient showed worsening of rest pain at 8 months. The last patient developed an arteriovenous shunt in the foot at 7 months, which spontaneously regressed by 1 year.

Conclusions— In the present unblinded and uncontrolled pilot study, long-term adverse events, including death and unfavorable angiogenesis, were observed in half of the patients receiving bone marrow mononuclear cell transplantation. Given the current incomplete knowledge of the safety and efficacy of this strategy, careful long-term monitoring is required for future patients receiving this treatment.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
J Am Coll Cardiol ImgHome page
J. R. Lindner, L. Womack, E. J. Barrett, J. Weltman, W. Price, N. L. Harthun, S. Kaul, and J. T. Patrie
Limb Stress-Rest Perfusion Imaging With Contrast Ultrasound for the Assessment of Peripheral Arterial Disease Severity
J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 343 - 350.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
C. M. Kramer
Skeletal Muscle Perfusion in Peripheral Arterial Disease: A Novel End Point for Cardiovascular Imaging
J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 351 - 353.
[Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006;114: 2679-2684
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2008; 20(1): 100 - 102.
[Abstract] [PDF]


Home page
JAMAHome page
R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
JAMA, February 27, 2008; 299(8): 925 - 936.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Kanayasu-Toyoda, A. Ishii-Watabe, T. Suzuki, T. Oshizawa, and T. Yamaguchi
A New Role of Thrombopoietin Enhancing ex Vivo Expansion of Endothelial Precursor Cells Derived from AC133-positive Cells
J. Biol. Chem., November 16, 2007; 282(46): 33507 - 33514.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. T. Hirsch
Critical Limb Ischemia and Stem Cell Research: Anchoring Hope With Informed Adverse Event Reporting
Circulation, December 12, 2006; 114(24): 2581 - 2583.
[Full Text] [PDF]